ACTRN12618000951257
Recruiting
未知
DEPART: Dupuytren’s disease Evaluation of Preventative or Adjuvant Radiation Therapy
Genesis Care0 sites568 target enrollmentJune 6, 2018
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Genesis Care
- Enrollment
- 568
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Eligibility – All groups \- (Prevention and Adjuvant)
- •\- Patient consent
- •\- No previous radiotherapy to the affected hand
- •\- No history of radiation sensitivity diseases (eg Scleroderma, Ataxia Telangiectasia, Li
- •\- Life expectancy \>5 years
- •\- Available and willing to participate in at least 5 years of follow\-up
- •\- Female patients capable of child\-bearing are not pregnant
- •Eligibility – Prevention Arm
- •\- Evidence of nodules and/or cords in the affected hand consistent with DD.
- •\- History of progressive DD over previous 6 months.
Exclusion Criteria
- •Previous radiotherapy in the affected hand/s
- •Previous surgery in the affected hand/s
- •History of radiation sensitivity diseases (eg Scleroderma, Ataxia Telangiectasia, Li Fraumeni)
- •Pregnant patients
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Dupuytren*s disease Evaluation of Preventative or Adjuvant Radiation TherapyDupuytren's diseaseViking disease10010761NL-OMON54267GenesisCare Cancer Care Research Pty Ltd100
Active, not recruiting
Not Applicable
Dupytren’s disease studyA randomized controlled study comparing enzyme treatment (with clostridium histolyticum) with needle transection of Dupytren’s finger contracture.EUCTR2013-001221-13-NOAkershus university hospital
Completed
Not Applicable
atural disease progress of Dupuytren's diseaseDupuytren's diseasefibromatosis palmaris10010761NL-OMON46937niversitair Medisch Centrum Groningen272
Recruiting
Phase 3
DupuytrEn Treatment EffeCtiveness Trial (DETECT)2024-515110-40-00Pirkanmaan hyvinvointialue, Pirkanmaan hyvinvointialue50
Recruiting
Not Applicable
A combination of pre-screening for DPD deficiency by genotyping/phenotyping methods and pharmacokinetics-guided dosing of 5-FU for precision treatment to prevent severe toxicity in gastrointestinal cancer patients.NL-OMON52496Isala Klinieken75